check_circleStudy Completed

Magnetic Resonance Imaging, Liver Neoplasms

Bayer Identifier:

90391

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Study to evaluate the diagnostic efficacy of Gd-EOB-DTPA in the characterization of focal liver lesions

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
235
Trial Dates
April 2000 - July 2001
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Eovist/Primovist (Gadoxetate disodium, BAY86-4873)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

A multi-center (US) open-label study of Gd-EOB-DTPA with a single intravenous injection (25 μmol/kg body weight) in patients with known or suspected focal liver lesions and the corresponding blinded reading to evaluate the diagnostic efficacy of Gd-EOB-DTPA in the characterization of focal liver lesions
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.